Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis

BACKGROUND: Breast cancer is the most prevalent type of cancer in women in the United States. Ribociclib plus fulvestrant combination therapy gained US Food and Drug Administration approval to treat postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2-negative...

Descripción completa

Detalles Bibliográficos
Autores principales: Berrios, Kevin, Burum, Alexandra, Jeong, Eunae, Zhong, Lixian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373030/
https://www.ncbi.nlm.nih.gov/pubmed/36282933
http://dx.doi.org/10.18553/jmcp.2022.28.11.1282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373030/
https://www.ncbi.nlm.nih.gov/pubmed/36282933
http://dx.doi.org/10.18553/jmcp.2022.28.11.1282

Ejemplares similares